TCGA-66-2757-01A-01R-0851-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 65
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.650
- MYC_TARGETS_V2+0.620
- MYC_TARGETS_V1+0.550
- G2M_CHECKPOINT+0.520
- DNA_REPAIR+0.480
- OXIDATIVE_PHOSPHORYLATION+0.300
- INTERFERON_ALPHA_RESPONSE+0.260
- MITOTIC_SPINDLE+0.130
- UNFOLDED_PROTEIN_RESPONSE+0.110
- PI3K_AKT_MTOR_SIGNALING+0.090
Top 10 suppressed
- ANGIOGENESIS-0.480
- COAGULATION-0.420
- TNFA_SIGNALING_VIA_NFKB-0.390
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.380
- HEDGEHOG_SIGNALING-0.370
- PANCREAS_BETA_CELLS-0.360
- INFLAMMATORY_RESPONSE-0.340
- MYOGENESIS-0.330
- CHOLESTEROL_HOMEOSTASIS-0.320
- COMPLEMENT-0.320
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR2016966 | — | — | 0.899 |
| 2 | 504282dd-4fef-4f70-a709-6a545d00a263 | — | — | 0.897 |
| 3 | TCGA-NC-A5HG-01A-11R-A26W-07 | — | cohortSQ1 | 0.896 |
| 4 | BS_DFGS950G | high-grade glioma | — | 0.894 |
| 5 | SRR8518219 | — | E | 0.891 |
| 6 | SRR33532767 | — | E | 0.885 |
| 7 | TCGA-22-5481-01A-31R-1949-07 | — | cohortMD1 | 0.884 |
| 8 | TCGA-21-1080-01A-01R-0692-07 | — | cohortSQ1 | 0.881 |
| 9 | BS_TZVFR600 | Med | Medulloblastoma | 0.876 |
| 10 | GSM6454749 | — | F | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 13 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.650 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.620 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.520 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.480 | Idelalisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.300 | Remibrutinib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.130 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.110 | Idelalisib | — uncovered |
| PI3K_AKT_MTOR_SIGNALING | 0.090 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.080 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.060 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.030 | Inavolisib | — uncovered |